Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Aug 25 (Reuters) - Royalty Pharma RPRX.O said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's AMGN.O drug for small cell lung cancer for up to $950 million.

The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, which won U.S. approval last year for patients with extensive-stage small cell lung cancer who have failed chemotherapy.